NASH
MCID: NNL006
MIFTS: 53

Non-Alcoholic Steatohepatitis (NASH)

Categories: Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Non-Alcoholic Steatohepatitis

MalaCards integrated aliases for Non-Alcoholic Steatohepatitis:

Name: Non-Alcoholic Steatohepatitis 12 53 17
Nash 12 53
Non-Alcoholic Fatty Liver Disease 53
Nonalcoholic Steatohepatitis 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0080547

Summaries for Non-Alcoholic Steatohepatitis

NIH Rare Diseases : 53 Nonalcoholic steatohepatitis, or NASH, is a common, often "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Non-Alcoholic Steatohepatitis, also known as nash, is related to viral hepatitis and hepatitis b. An important gene associated with Non-Alcoholic Steatohepatitis is INS (Insulin), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Milk thistle and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cellular

Disease Ontology : 12 A nonalcoholic fatty liver disease that is characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without any fibrosis.

Related Diseases for Non-Alcoholic Steatohepatitis

Diseases related to Non-Alcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 31.3 TNF SLC17A5 GPT
2 hepatitis b 31.0 TNF SLC17A5 GPT
3 hepatitis 30.8 TNF SLC17A5 GPT
4 infantile liver failure syndrome 1 30.7 SLC17A5 GPT
5 liver cirrhosis 30.7 SLC17A5 GPT ADIPOQ
6 peripheral nervous system disease 30.6 TNF INS IL6
7 fatty liver disease, nonalcoholic 1 30.5 SLC17A5 PPARA INS GPT ADIPOQ
8 autoimmune gastritis 30.5 TNF IL6
9 autoimmune disease 30.4 TNF INS IL6
10 cholangitis 30.4 TNF IL6 GPT
11 viral infectious disease 30.4 TNF IL6 GPT
12 periodontitis 30.3 TNF IL6 CCL2
13 alcoholic hepatitis 30.3 TNF SLC17A5 IL6 GPT CCL2
14 fatty liver disease 30.2 TNF SLC17A5 PPARA INS IL6 ADIPOQ
15 pulmonary disease, chronic obstructive 30.2 TNF IL6 CCL2
16 hepatic encephalopathy 30.2 TNF SLC17A5 IL6 GPT
17 familial hyperlipidemia 30.2 PPARA PON1 INS
18 ovarian disease 30.2 TNF PTEN INS
19 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.2 INS ADIPOQ
20 pyelonephritis 30.1 TNF IL6 CCL2
21 peritonitis 30.1 TNF IL6 CCL2
22 glucose intolerance 30.1 PPARG INS ADIPOQ
23 gastrointestinal system disease 30.1 TNF INS IL6
24 lung disease 30.1 TNF IL6 CCL2
25 bacterial infectious disease 30.1 TNF IL6 CCL2
26 pneumonia 30.0 TNF IL6 CCL2
27 abdominal obesity-metabolic syndrome 1 30.0 PPARG INS ADIPOQ
28 lipid metabolism disorder 30.0 PPARG PPARA INS ADIPOQ
29 hyperglycemia 30.0 PPARG INS ADIPOQ
30 heart disease 29.9 TNF PON1 INS IL6
31 sleep apnea 29.8 TNF INS IL6 ADIPOQ
32 acanthosis nigricans 29.6 PPARG INS ADIPOQ
33 acquired generalized lipodystrophy 29.5 PPARG INS ADIPOQ
34 liver disease 29.5 TNF SLC17A5 PPARA INS IL6 GPT
35 kidney disease 29.5 INS IL6 CCL2 ADIPOQ
36 coronary heart disease 1 29.4 PON1 INS IL6 ADIPOQ
37 apnea, obstructive sleep 29.3 TNF INS IL6 ADIPOQ
38 cerebrovascular disease 29.0 TNF PON1 INS IL6 ADIPOQ
39 glucose metabolism disease 28.6 TNF PPARG INS IL6 ADIPOQ
40 arteries, anomalies of 28.2 TNF PPARG PON1 INS IL6 CCL2
41 large intestine cancer 28.1 TNF PTEN PPARG INS IL6 ADIPOQ
42 myocardial infarction 28.0 TNF PON1 INS IL6 CCL2 ADIPOQ
43 vascular disease 28.0 TNF PPARG PON1 INS IL6 CCL2
44 diabetes mellitus 28.0 TNF PPARG PPARA PON1 INS IL6
45 overnutrition 27.6 TNF PPARG PPARA INS IL6 CCL2
46 acquired metabolic disease 27.5 TNF PPARG PPARA INS IL6 CCL2
47 proteasome-associated autoinflammatory syndrome 1 27.4 TNF PPARG PPARA INS IL6 CCL2
48 atherosclerosis susceptibility 27.2 TNF PPARG PPARA PON1 INS IL6
49 arteriosclerosis 27.1 PPARG PPARA PON1 INS IL6 CCL2
50 body mass index quantitative trait locus 11 26.7 TNF PPARG PPARA PON1 INS IL6

Graphical network of the top 20 diseases related to Non-Alcoholic Steatohepatitis:



Diseases related to Non-Alcoholic Steatohepatitis

Symptoms & Phenotypes for Non-Alcoholic Steatohepatitis

GenomeRNAi Phenotypes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 INS PTEN TNF

MGI Mouse Phenotypes related to Non-Alcoholic Steatohepatitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 ADIPOQ IL6 INS PON1 PPARA PPARG
2 cardiovascular system MP:0005385 10.1 ADIPOQ IL6 INS PON1 PPARA PPARG
3 homeostasis/metabolism MP:0005376 10.09 ADIPOQ IL6 INS PON1 PPARA PPARG
4 growth/size/body region MP:0005378 10.06 ADIPOQ IL6 INS PPARA PPARG PTEN
5 adipose tissue MP:0005375 10.05 ADIPOQ IL6 INS PPARA PPARG PTEN
6 immune system MP:0005387 10.01 ADIPOQ CCL2 IL6 INS PPARA PPARG
7 integument MP:0010771 9.91 ADIPOQ IL6 INS PPARA PPARG PTEN
8 liver/biliary system MP:0005370 9.87 ADIPOQ IL6 INS PPARA PPARG PTEN
9 muscle MP:0005369 9.8 ADIPOQ IL6 INS PPARA PPARG PTEN
10 neoplasm MP:0002006 9.55 ADIPOQ IL6 PPARG PTEN TNF
11 skeleton MP:0005390 9.5 ADIPOQ GPT IL6 INS PPARG PTEN
12 vision/eye MP:0005391 9.1 IL6 INS PPARG PTEN SLC17A5 TNF

Drugs & Therapeutics for Non-Alcoholic Steatohepatitis

Drugs for Non-Alcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Liraglutide Approved Phase 4 204656-20-2 44147092
6
Glucagon Approved Phase 4 16941-32-5
7
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
8
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
9
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Insulin Detemir Approved Phase 4 169148-63-4 5311023
12
Insulin Aspart Approved Phase 4 116094-23-6 16132418
13
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
14
Ribavirin Approved Phase 4 36791-04-5 37542
15
Gliclazide Approved Phase 4 21187-98-4 3475
16
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Ethanol Approved Phase 4 64-17-5 702
19
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
20
Glimepiride Approved Phase 4 93479-97-1 3476
21
Phentermine Approved, Illicit Phase 4 122-09-8 4771
22
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
23
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
24
Testosterone enanthate Approved Phase 4 315-37-7 9416
25
Methyltestosterone Approved Phase 4 58-18-4 6010
26
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
27
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
28
Alogliptin Approved Phase 4 850649-61-5 11450633
29
Dulaglutide Approved, Investigational Phase 4 923950-08-7
30
Empagliflozin Approved Phase 4 864070-44-0
31
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
32
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
33
Metformin Approved Phase 4 657-24-9 4091 14219
34
Zinc Approved, Investigational Phase 4 7440-66-6 32051
35
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
36
Insulin glargine Approved Phase 4 160337-95-1
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38
Choline Approved, Nutraceutical Phase 4 62-49-7 305
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
40
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
41
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
42
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
43
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45 Ipragliflozin Investigational Phase 4 761423-87-4
46
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
47
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
48 Platelet Aggregation Inhibitors Phase 4
49 Vasodilator Agents Phase 4
50 Nootropic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 900)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
3 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
4 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
5 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
7 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
8 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
9 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
10 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
11 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
12 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
13 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
14 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
15 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
16 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
17 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
18 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
19 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
20 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
21 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
22 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
23 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
24 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
25 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
26 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
27 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
28 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
29 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
30 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
31 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
32 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
33 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
34 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
35 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
36 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
37 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
38 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
39 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
40 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
41 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
42 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
43 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
44 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
45 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
46 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
47 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
48 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine
49 Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion Recruiting NCT02500147 Phase 4 Metformin;Placebo
50 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Recruiting NCT02984475 Phase 4 Metformin

Search NIH Clinical Center for Non-Alcoholic Steatohepatitis

Genetic Tests for Non-Alcoholic Steatohepatitis

Anatomical Context for Non-Alcoholic Steatohepatitis

MalaCards organs/tissues related to Non-Alcoholic Steatohepatitis:

41
Liver, Testes, Kidney, Endothelial, Heart, Bone, T Cells

Publications for Non-Alcoholic Steatohepatitis

Articles related to Non-Alcoholic Steatohepatitis:

(show top 50) (show all 8054)
# Title Authors PMID Year
1
Fibroblast growth factor 21 for non-alcoholic steatohepatitis. 38
30554786 2019
2
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. 38
30554783 2019
3
Joint Pricing and Decision-Making for Heterogeneous User Demand in Cognitive Radio Networks. 38
30010609 2019
4
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. 38
31325638 2019
5
Ascorbic acid attenuates cell stress by activating the fibroblast growth factor 21/fibroblast growth factor receptor 2/adiponectin pathway in HepG2 cells. 38
31322211 2019
6
Role and effective therapeutic target of gut microbiota in NAFLD/NASH. 38
31410156 2019
7
High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. 38
30919112 2019
8
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. 38
30778201 2019
9
Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. 38
30888972 2019
10
Epoxyeicosatrienoic acids alleviate methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice. 38
31132306 2019
11
Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator? 38
31087761 2019
12
Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis. 38
31414538 2019
13
Management of metabolic syndrome and cardiovascular risk after liver transplantation. 38
31387736 2019
14
Adenovirus‑mediated overexpression of bone morphogenetic protein‑9 promotes methionine choline deficiency‑induced non‑alcoholic steatohepatitis in non‑obese mice. 38
31322255 2019
15
Adult liver transplant for hepatocellular carcinoma at Wits Donald Gordon Medical Centre in Johannesburg, South Africa. 38
31392858 2019
16
Nonalcoholic Fatty Liver Disease and Obesity Treatment. 38
30945129 2019
17
Understanding Environmental Contaminants' Direct Effects on Non-alcoholic Fatty Liver Disease Progression. 38
31090041 2019
18
Melatonin prevents chronic intermittent hypoxia-induced injury by inducing sirtuin 1-mediated autophagy in steatotic liver of mice. 38
30411173 2019
19
Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis. 38
31233751 2019
20
Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study. 38
30019089 2019
21
Antifibrotic Effects of 1,25(OH)2D3 on Nonalcoholic Steatohepatitis in Female Mice. 38
30825110 2019
22
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? 38
31301336 2019
23
How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. 38
31382287 2019
24
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). 38
31394730 2019
25
Pinolenic acid ameliorates oleic acid-induced lipogenesis and oxidative stress via AMPK/SIRT1 signaling pathway in HepG2 cells. 38
31430456 2019
26
Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis. 38
31139863 2019
27
CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation. 38
31422074 2019
28
AdipoRon prevents myostatin-induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line. 38
31250564 2019
29
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. 38
31071367 2019
30
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. 38
30556145 2019
31
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. 38
31332029 2019
32
Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. 38
30830270 2019
33
CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. 38
31402538 2019
34
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. 38
30848827 2019
35
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. 38
30549292 2019
36
Are Lifestyle Therapies Effective for NAFLD Treatment? 38
31422872 2019
37
Laparoscopic Sleeve Gastrectomy on the Horizon as a Promising Treatment Modality for NAFLD. 38
31372873 2019
38
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. 38
31388629 2019
39
Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand? 38
31229271 2019
40
Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor. 38
31294056 2019
41
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. 38
31419514 2019
42
Validation of the chronic liver disease questionnaire for non-alcoholic steatohepatitis in patients: impact for the clinic. 38
31248299 2019
43
Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. 38
28833326 2019
44
Melon GliSODin® Prevents Diet-Induced NASH Onset by Reducing Fat Synthesis and Improving Liver Function. 38
31374969 2019
45
Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. 38
31390551 2019
46
A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity. 38
31376210 2019
47
Key Relevance of Epigenetic Programming of Adiponectin gene in Pathogenesis of Metabolic disorders. 38
31368881 2019
48
Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. 38
31207429 2019
49
Apolipoprotein A-I improves hepatic autophagy through the AMPK pathway. 38
31401190 2019
50
Effect of curcumin supplementation on serum expression of select cytokines and chemokines in a female rat model of nonalcoholic steatohepatitis. 38
31399137 2019

Variations for Non-Alcoholic Steatohepatitis

Expression for Non-Alcoholic Steatohepatitis

Search GEO for disease gene expression data for Non-Alcoholic Steatohepatitis.

Pathways for Non-Alcoholic Steatohepatitis

Pathways related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 TNF PPARG PPARA INS IL6 ADIPOQ
2
Show member pathways
12.44 TNF PTEN INS IL6 ADIPOQ
3 12.31 PTEN PPARG INS ADIPOQ
4
Show member pathways
12.09 TNF INS IL6 CCL2
5
Show member pathways
11.98 PPARG INS ADIPOQ
7
Show member pathways
11.92 PTEN INS IL6
8 11.85 TNF IL6 CCL2
9 11.82 TNF IL6 CCL2
10 11.8 TNF IL6 CCL2
11 11.77 PTEN INS IL6
12 11.73 TNF IL6 CCL2
13
Show member pathways
11.71 TNF INS ADIPOQ
14 11.68 TNF IL6 CCL2
15
Show member pathways
11.6 TNF PTEN PPARA INS IL6
16 11.57 PPARG PPARA ADIPOQ
17 11.51 TNF PPARA ADIPOQ
18 11.47 TNF PPARG IL6 CCL2
19 11.45 TNF IL6 CCL2
20 11.3 TNF IL6 CCL2
21 11.27 TNF IL6 CCL2
22 11.22 TNF PPARG PPARA INS IL6 ADIPOQ
23 11.1 TNF IL6
24 11.04 TNF IL6 CCL2
25 11.03 PPARG ADIPOQ
26 10.9 TNF IL6
27 10.81 TNF CCL2
28 10.8 INS GPT
29 10.6 TNF PPARG IL6 ADIPOQ

GO Terms for Non-Alcoholic Steatohepatitis

Cellular components related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 TNF PTEN PON1 INS IL6 CCL2
2 extracellular space GO:0005615 9.17 TNF PON1 INS IL6 GPT CCL2

Biological processes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.99 TNF PPARG PPARA ADIPOQ
2 lipid metabolic process GO:0006629 9.97 PTEN PPARG PPARA PON1
3 positive regulation of gene expression GO:0010628 9.93 TNF PTEN INS IL6
4 positive regulation of apoptotic process GO:0043065 9.88 TNF PTEN PPARG IL6
5 cellular response to lipopolysaccharide GO:0071222 9.84 TNF IL6 CCL2
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF INS IL6
7 glucose homeostasis GO:0042593 9.77 PPARG INS ADIPOQ
8 response to bacterium GO:0009617 9.77 SLC17A5 CCL2 ADIPOQ
9 response to organic substance GO:0010033 9.75 TNF PTEN PPARG
10 cellular response to insulin stimulus GO:0032869 9.74 PTEN PPARG ADIPOQ
11 response to nutrient GO:0007584 9.72 PTEN PPARG ADIPOQ
12 negative regulation of blood pressure GO:0045776 9.68 PPARA ADIPOQ
13 positive regulation of interleukin-8 production GO:0032757 9.68 TNF ADIPOQ
14 positive regulation of cytokine secretion GO:0050715 9.68 TNF INS
15 negative regulation of vascular endothelial cell proliferation GO:1905563 9.68 PPARG CCL2
16 negative regulation of neurogenesis GO:0050768 9.67 TNF IL6
17 response to lipid GO:0033993 9.67 PPARG PPARA
18 positive regulation of chemokine production GO:0032722 9.66 TNF IL6
19 positive regulation of glial cell proliferation GO:0060252 9.65 TNF IL6
20 positive regulation of cellular protein metabolic process GO:0032270 9.65 INS ADIPOQ
21 response to glucocorticoid GO:0051384 9.65 TNF IL6 ADIPOQ
22 negative regulation of lipid catabolic process GO:0050995 9.64 TNF INS
23 negative regulation of collagen biosynthetic process GO:0032966 9.64 PPARG IL6
24 fatty acid oxidation GO:0019395 9.63 PPARG ADIPOQ
25 glucose metabolic process GO:0006006 9.63 TNF INS ADIPOQ
26 positive regulation of cholesterol efflux GO:0010875 9.62 PON1 ADIPOQ
27 negative regulation of phagocytosis GO:0050765 9.62 PTEN ADIPOQ
28 negative regulation of gluconeogenesis GO:0045721 9.61 INS ADIPOQ
29 regulation of protein secretion GO:0050708 9.61 TNF INS
30 humoral immune response GO:0006959 9.58 TNF IL6 CCL2
31 negative regulation of lipid storage GO:0010888 9.56 TNF IL6
32 negative regulation of cholesterol storage GO:0010887 9.54 PPARG PPARA
33 negative regulation of fat cell differentiation GO:0045599 9.54 TNF IL6 ADIPOQ
34 negative regulation of acute inflammatory response GO:0002674 9.52 PPARG INS
35 positive regulation of neuroinflammatory response GO:0150078 9.51 TNF IL6
36 positive regulation of fatty acid oxidation GO:0046321 9.49 PPARG PPARA
37 negative regulation of sequestering of triglyceride GO:0010891 9.43 PPARG PPARA
38 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.43 PTEN PPARG ADIPOQ
39 protein kinase B signaling GO:0043491 9.33 TNF PTEN CCL2
40 negative regulation of receptor biosynthetic process GO:0010871 9.32 PPARG PPARA
41 positive regulation of DNA-binding transcription factor activity GO:0051091 9.26 TNF PTEN PPARG IL6
42 negative regulation of macrophage derived foam cell differentiation GO:0010745 8.8 PPARG PPARA ADIPOQ

Molecular functions related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.35 TNF PTEN PPARG INS ADIPOQ
2 fatty acid binding GO:0005504 9.16 PPARG PPARA
3 cytokine activity GO:0005125 8.92 TNF IL6 CCL2 ADIPOQ

Sources for Non-Alcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....